Table 1 |
F-MIC S</R> |
Enterobac- teriaceae |
Pseudo- monas |
Acineto- bacter |
Staphylo- coccus |
Entero- coccus |
Strepto- coccus |
Pneumo- coccus |
H.influ- enzae |
M.ca- tarrhal |
C.ureal C.jeikei |
N.gonor- rhoeae |
N.menin- gitidis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Method (see below) | A | A | A | A | A | B | B | B | B | B | B
for nalidixic acid screen |
B | |
| Penicillin G | 1/4 | -- | -- | -- | -- | 0.25/4 | 0.25/1 | 0.06/1 | 1/1 | m.cat | IE | 0.06/1 | 0.25/1 |
| Penicillin V | 0.25/4 | -- | -- | -- | -- | -- | 0.25/1 | 0.06/1 | 0.5/4 | m.cat | IE | -- | 1/1 |
| Oxacillin | 1/1 | -- | -- | -- | -- | -- | 1/1 | oxa | -- | -- | -- | -- | -- |
| Cefoxitin | -- | -- | -- | -- | 4/4 | -- | -- | -- | -- | -- | -- | -- | -- |
| Ampicillin | 2/8 | 1/8 | -- | -- | -- S.sapro 0.5/0.5 |
2/8 | 0.25/1 | 0.06/1 | 0.5/0.5 | m.cat | IE | 0.12/2 | -- |
| Mecillinam | 1/8 | 1/8 | -- | -- | S.sapro | -- | -- | -- | -- | -- | -- | -- | -- |
| Piperacillin/ tazobactam |
16/16 | 16/16 | 16/16 | 16/32 | cefox | 16/16 | 0.25/1 | 0.06/1 | IE | IE | IE | -- | -- |
| Imipenema+ | 2/8 | 2/8a | 4/8 | 2/8 | cefox | 4/8 | 2/2 | 2/2 | 2/2 | 2/2 | IE | IE | -- |
| Meropenem+ | 2/8 | 2/8 | 2/8 | 2/8 | cefox | -- | 2/2 | 2/2 | 2/2 | 2/2 | IE | IE | 0.25/0.25 |
| Ertapenem+ | 0.5/1 | 0.5/1 | -- | -- | cefox | -- | 0.5/0.5 | 0.5/0.5 | 0.5/0.5 | 0.5/0.5 | IE | IE | -- |
| Aztreonam+ | 4/8 | 1/8 | 1/16 | -- | -- | -- | -- | -- | IE | IE | -- | IE | -- |
| F-MIC |
Enterobac- teriaceae |
Pseudo- monas |
Acineto- bacter |
Staphylo- coccus |
Entero- coccus |
Strepto- coccus |
Pneumo- coccus |
H.influ- enzae |
M.ca- tarrhal |
C.ureal C.jeikei |
N.gonor- rhoeae |
N.menin- gitidis |
|
| Cefalotin | 1/8 | 1/8 | -- | -- | cefox | -- | 0.5/1 | 0.25/1 | -- | -- | IE | -- | -- |
| Cefalexin | 1/8 | 1/8 | -- | -- | cefox | -- | 1/1 | 1/1 | -- | -- | IE | -- | -- |
| Cefadroxil | 1/8 | 1/8 | -- | -- | cefox | -- | 1/1 | 1/1 | -- | IE | IE | -- | -- |
| Lorakarbef | 2/4 | 2/4 | -- | -- | cefox | -- | 1/1 | 1/1 | 2/4 | 2/4 | IE | -- | -- |
| Cefuroxim-axetil | 2/2 | -- | -- | -- | cefox | -- | 0.12/2 | 0.12/0.25 | 2/2 | 2/2 | IE | -- | -- |
| Cefpodoximb | 1/2 | 1/2 | -- | -- | cefox | -- | 0.06/1 | 0.06/0.12 | 0.25/0.5 | 1/2 | IE | -- | -- |
| Ceftibuten | 1/4 | 1/4 | -- | -- | -- | -- | 1/4 | -- | 0.25/0.5 | 1/4 | IE | -- | -- |
| Cefuroxim+ | 4/8 | 8/8c | -- | -- | cefox | -- | 0.5/0.5 | 0.5/1 | 1/2 | 1/2 | IE | -- | -- |
| Cefotaxim+ | 1/2 | 1/2 | -- | -- | cefox | -- | 0.5/0.5 | 0.5/2 | 0.12/0.12 | 0.12/0.12 | IE | 0.12/0.12 | 0.12/0.12 |
| Ceftriaxon+ | 1/2 | 1/2 | -- | -- | cefox | -- | 0.5/0.5 | 0.5/2 | 0.12/0.12 | 0.12/0.12 | IE | 0.12/0.12 | 0.12/0.12 |
| Ceftazidim+ | 4/8 | 1/8 | 8/8 | -- | cefox | -- | -- | -- | -- | -- | IE | -- | -- |
| Cefepim+ | 4/8 | 1/8 | 8/8 | -- | cefox | -- | 0.5/0.5 | 1/2 | 0.25/0.25 | 0.25/0.25 | IE | -- | -- |
| Cefiximd | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.06/0.5 | -- |
+MIC breakpoints harmonised through the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
aProteus
and Morganella species are considered poor targets for imipenem and
testing should be avoided.
bCefpodoxime is no longer registered.
cCefuroxime
Enterobacteriaceae breakpoints are valid for Escherichia coli,
Klebsiella spp and Proteus mirabilis in infections originating from the urinary tract and for a
dosage of 1.5 g x 3 or more.
dEnbart på
licens för behandling av gonorré
| Listeria Medium B |
Penicillin G (2/2), Ampicillin (2/2), Meropenem (0.5/0.5), TrimSulfa (2/4). Vid allergi hos gravida Erythromycin (0.5/0.5) som har sämre klinisk effekt. (EUCAST MIC-distributions for Listeria monocytogenes. |
| P.multocida Medium B |
Penicillin V (0.5/0.5), Ampicillin (0.5/0.5), Cefotaxime (0.12/1), Ciprofloxacin (0.12/0.25), Tetracycline (2/4) och TrimSulfa (2/4). (EUCAST MIC-distributions for P.multocida. |
| H.pylori Medium B |
Ampicillin (0.5/1), Clarithromycin (0.25/0.25), Tetracycline (2/2), Metronidazole (4/4) (EUCAST MIC-distributions for H. pylori.) |
| Legionella pneumophila | See MIC-distributions for relevant antimicrobials (EUCAST MIC-distributions for L. pneumophila) |
| Bacteroides, Clostridium Medium B + Anaerobe incubation |
Penicillin G for Clostridium (0.25/1), Piperacillin/tazobactam (16/16), Imipenem (1/1), Meropenem (1/1), Clindamycin for Bacteroides 4/4, Clindamycin for Clostridium 4/4, Chloramphenicole (8/8), Tetracycline (2/2; proposed change: IE), Doxycycline (1/2; proposed change: IE), Metronidazole (4/4) |
| Stenotrophomonas maltophilia | Trimsulfa 4/4 mg/L (MIC-tests should be performed on Mueller-Hinton agar). Breakpoints for other antimicrobials are not given by SRGA or EUCAST. Clinical correlation between MIC-values and clinical outcome is lacking and testing is uncertain. When testing, always use Mueller Hinton medium. |
Kursiv text anger en länk till en fotnot. För den som skriver ut tabellen på papper är det viktigt att även alla fotnoter skrivs ut och följer med tabellen. |
Text = a link to a footnote. If you print the table on paper, remember to print the footnotes - they contain important information on methodology. |
| 4/8 - sättet att beskriva
MIC-gränser (exempelvis 4/8) skall tolkas S<
4 och R>8
mg/L (N.B. R> ändrades 2003 till R>) IE - Klinisk effekt utesluts ej men in vitro och/eller in vivo dokumentation saknas. -- RAF avråder från resistensbestämning. Ej relevant behandlingsalternativ:
|
4/8 - breakpoints
for SIR-categorisation: S< 4 mg/l and
R>8 mg/L.
(R> was changed in 2003 to R>). IE - Clinical effect is not ruled out but EUCAST/SRGA have not been able to find enough clinical evidence to determine a breakpoint. -- SRGA advices against susceptibility testing. Not a relevant alternative:
|
|
Metod: A = grundmedium utan tillsatser. Inkubation 35 - 37o C i luft. B = grundmedium + 5% skakhästblod.+ NAD. Inkubation i 5 % CO2 vid 35 - 37o C . |
Method: A = medium without additives. Incubation in air, 35 - 37oC. B = medium + 5% defibrinated horse blood + NAD. Incubation in 5 % CO2 at 35 - 37oC. |
